Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DYAI 
Dyadic International Inc (DYAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: DYAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.17% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.60M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 38309 | Beta 0.72 | 52 Weeks Range 0.93 - 2.67 | Updated Date 03/30/2025 |
52 Weeks Range 0.93 - 2.67 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate - | Actual -0.052 |
Profitability
Profit Margin - | Operating Margin (TTM) -528.5% |
Management Effectiveness
Return on Assets (TTM) -46.28% | Return on Equity (TTM) -127.38% |
Valuation
Trailing PE - | Forward PE 15.82 | Enterprise Value 37328002 | Price to Sales(TTM) 11.88 |
Enterprise Value 37328002 | Price to Sales(TTM) 11.88 | ||
Enterprise Value to Revenue 10.68 | Enterprise Value to EBITDA -2.93 | Shares Outstanding 29477600 | Shares Floating 18981241 |
Shares Outstanding 29477600 | Shares Floating 18981241 | ||
Percent Insiders 30.21 | Percent Institutions 16.01 |
Analyst Ratings
Rating 4 | Target Price 6 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Dyadic International Inc
Company Overview
History and Background
Dyadic International Inc. was founded in 1979. Initially focused on industrial enzymes, it transitioned to developing and commercializing the C1 gene expression platform for biopharmaceutical and industrial applications. Significant milestones include the development and validation of the C1 technology and partnerships with various companies for research and development.
Core Business Areas
- C1 Technology Platform: Dyadic's core business revolves around its patented C1 gene expression platform, a fungal-based technology for producing enzymes and other proteins used in the biopharmaceutical, animal health, and industrial biotechnology industries.
Leadership and Structure
Mark Emalfarb serves as the Chief Executive Officer and founder. The company operates with a management team focused on research and development, business development, and strategic partnerships. They rely heavily on collaborative research agreements.
Top Products and Market Share
Key Offerings
- C1 Expression Platform: The C1 platform is Dyadic's primary offering. It allows for rapid and cost-effective production of various proteins and enzymes. C1 platform has partnered research programs for human and animal vaccines, biosimilars and pharmaceutical proteins. Competitors include companies using mammalian cell culture (e.g., CHO cells), E. coli, and yeast-based expression systems (e.g., Pichia pastoris). Difficult to ascertain market share due to its position as technology platform used within other products.
Market Dynamics
Industry Overview
The biopharmaceutical and industrial enzyme markets are experiencing growth driven by increasing demand for biologics, vaccines, and sustainable industrial processes. Advances in gene expression technologies and biomanufacturing are shaping the competitive landscape.
Positioning
Dyadic positions itself as a provider of a cost-effective and scalable alternative to traditional expression systems. Its C1 platform aims to improve the economics and efficiency of biomanufacturing.
Total Addressable Market (TAM)
The TAM for biopharmaceutical manufacturing is expected to reach hundreds of billions of dollars. Dyadic's platform is positioned to capture a portion of this market by offering a more efficient and cost-effective production method. Exact TAM quantification for C1 is difficult but is related to the recombinant protein production market.
Upturn SWOT Analysis
Strengths
- Proprietary C1 gene expression platform
- Potential for lower production costs compared to traditional methods
- Scalability of the C1 platform
- Partnerships with established companies
Weaknesses
- Reliance on partnerships for revenue generation
- Limited number of commercialized products directly attributable to Dyadic
- Dependence on successful validation and adoption of C1 platform
- Limited financial resources compared to larger competitors
Opportunities
- Expanding applications of C1 platform in biopharmaceuticals and industrial enzymes
- Increased demand for cost-effective biomanufacturing solutions
- Strategic alliances and licensing agreements
- Developing proprietary products based on C1 technology
Threats
- Competition from established expression systems
- Regulatory hurdles for new biomanufacturing processes
- Potential obsolescence of technology
- Failure of partnerships to yield commercial success
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Merck KGaA (MRK.DE)
- Danaher Corporation (DHR)
Competitive Landscape
Dyadic's C1 platform offers a potential cost advantage, but it faces competition from established players with well-validated and widely adopted technologies. Differentiation through specialized applications and strategic partnerships is crucial.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical Growth has been inconsistent with limited product sales and fluctuating revenues tied to partnership agreements and licensing fees. Therefore, no specific growth data.
Future Projections: Future Projections are dependent on the success of ongoing research collaborations and the commercialization of products developed using the C1 platform. No external estimates provided for the company.
Recent Initiatives: Focus on developing C1-based solutions for COVID-19 vaccines and therapeutics, expansion of animal health applications, and collaborations with pharmaceutical companies.
Summary
Dyadic International Inc. is a biotech company with a promising C1 gene expression platform. The company faces challenges due to its dependence on licensing agreements, but its unique technology offers cost and scalability advantages. Future success hinges on the successful development and commercialization of products through ongoing partnerships and internal development efforts. Continued validation of C1 platform and financial stability are key to long-term growth.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyadic International Inc
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2004-11-05 | Founder, CEO, President & Director Mr. Mark A. Emalfarb | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.dyadic.com |
Full time employees - | Website https://www.dyadic.com | ||
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.